Price Chart

Executive Summary

CG Oncology upsized its at-the-market (ATM) equity offering by $500M to a total of $1.05B, after already selling $550M in gross proceeds via 10.8M shares. The additional capacity represents potential dilution of up to ~7.8% of shares outstanding at current prices, with proceeds earmarked for general corporate purposes including R&D and commercialization of its lead candidate, cretostimogene. The massive capital raise signals aggressive funding needs and will likely pressure the stock as the market absorbs the supply over time.

Key Facts

• ATM offering capacity increased by $500M to a total of $1.05B (Amendment No. 2 to Prospectus).
• Already sold 10,800,525 shares for gross proceeds of $550M under the existing ATM agreement.
• At the August 5, 2026 closing price of $72.42, the additional $500M capacity represents up to ~6.9M shares, or ~7.8% of the 88.0M shares outstanding as of March 31, 2026.
• Proceeds intended for general corporate purposes, including R&D and commercialization of cretostimogene.
• New investors would experience immediate dilution of $55.92 per share at the assumed offering price of $72.42.
• Jefferies LLC acts as sales agent with a 3.0% commission on gross proceeds.

Financial Impact

Up to $500M in additional common stock sales, potentially diluting existing shareholders by ~7.8% at current prices. Total ATM capacity now $1.05B.

Risk Factors

• Substantial dilution from the full $500M ATM tranche if sold at current prices.
• Lack of near-term revenue or profitability increases reliance on equity financing.
• Market may interpret aggressive capital raising as a sign of higher cash burn or delayed milestones.

Market Snapshot

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

US Market Status